Latest Articles

Publication Date
Hypersensitive intercellular responses of endometrial stromal cells drive invasion in Endometriosis.

Endometriosis is a debilitating disease affecting 190 million women worldwide and the greatest single contributor to infertility. The most broadly accepted etiology is that uterine endometrial cells retrogradely enter the …

Published: Dec. 11, 2024, midnight
Catamenial Pneumothorax in a Patient Undergoing Low-Dose Estrogen-Progestin Therapy: A Case Report.

A 46-year-old woman on low-dose estrogen-progestin (LEP) therapy for endometriosis developed a right-sided pneumothorax. Surgical findings included a pulmonary bulla in the right middle lung lobe and a small hole …

Published: Dec. 11, 2024, midnight
Primary Umbilical Endometriosis (Villar's Nodule): A Case Report.

Primary umbilical endometriosis is a rare condition in which there is endometrial glands and stroma in the umbilicus. Primary umbilical endometriosis is also called villar's nodule. This condition is a …

Published: Dec. 11, 2024, midnight
Peri-implantation treatment with TNF-α inhibitor for endometriosis and/or adenomyosis women undergoing frozen-thawed embryo transfer: A retrospective cohort study.

Endometriosis and adenomyosis have common pathogenesis and close relationship, with multi-factors involved in related infertility and IVF failure. They lead to anatomical changes, ovarian reserve reduction, endocrine abnormalities, altered endometrial …

Published: Dec. 11, 2024, midnight
Early Recurrence After Surgery in FIGO 2023 Stage I-III Endometrial Cancer: Characteristics and risk factors - Frontiers

Early Recurrence After Surgery in FIGO 2023 Stage I-III Endometrial Cancer: Characteristics and risk factors Frontiers

Published: Dec. 10, 2024, 4:36 p.m.
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - BioSpace

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer BioSpace

Published: Dec. 10, 2024, 12:23 p.m.
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - Yahoo Finance

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer Yahoo Finance

Published: Dec. 10, 2024, 11 a.m.
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PR Newswire

IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer PR Newswire

Published: Dec. 10, 2024, 11 a.m.
IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer - StockTitan

IDEAYA Launches Breakthrough Phase 1 Trial: Novel PARG Inhibitor + KEYTRUDA for Endometrial Cancer StockTitan

Published: Dec. 10, 2024, 11 a.m.
Endometrial Cancer Market: Opportunities, Challenges, - openPR

Endometrial Cancer Market: Opportunities, Challenges, openPR

Published: Dec. 10, 2024, 7:16 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!